Results 151 to 160 of about 1,369,314 (252)

Effects of esaxerenone add‐on therapy versus angiotensin II receptor blocker dose escalation on albuminuria and blood pressure in hypertensive patients with type 2 diabetes: An exploratory randomized study

Journal of Diabetes Investigation, EarlyView.
ABSTRACT Aims Residual albuminuria remains a major clinical challenge in patients with type 2 diabetes mellitus and hypertension despite renin–angiotensin system inhibitor therapy. Esaxerenone, a selective nonsteroidal mineralocorticoid receptor antagonist, reduces albuminuria; however, its effects on oxidative stress remain unclear.
Makoto Ohara, Takemasa Omachi, Nobuaki Takehana, Tomoki Fujikawa, Naoya Osaka, Shunichiro Irie, Michishige Terasaki, Yusaku Mori, Takanori Matsui, Sho‐ichi Yamagishi   +9 more
wiley   +1 more source

Identification of novel triazolopyrimidines as potent α-glucosidase inhibitor through design, synthesis, biological evaluations, and computational analysis. [PDF]

Sci Rep
Peytam F, Norouzbahari M, Gulcan HO, Hosseini FS, Moghadam MS, Mojtabavi S, Faramarzi MA, Ghasemi F, Torabi M, Sadat-Ebrahimi SE, Tehrani MB, Firoozpour L, Foroumadi A.   +12 more
europepmc   +1 more source

TLC-MS Bioautography-Based Identification of Free-Radical Scavenging, α-Amylase, and α-Glucosidase Inhibitor Compounds of Antidiabetic Tablet BGR-34. [PDF]

ACS Omega, 2020
Gaurav, Zahiruddin S, Parveen B, Ibrahim M, Sharma I, Sharma S, Sharma AK, Parveen R, Ahmad S.   +8 more
europepmc   +1 more source

Comparative Effectiveness of GLP‐1RAs, SGLT2is and DPP4is for Cardiovascular Outcomes in Type 2 Diabetes: An Empirically Calibrated Target Trial Emulation Study

Diabetes, Obesity and Metabolism, EarlyView.
Bingyu Zhang, Ting Zhou, Huilin Tang, Yiwen Lu, Dazheng Zhang, Jiajie Chen, Tianchu Lyu, Kai Zheng, David A. Asch, Yong Chen   +9 more
wiley   +1 more source

Temporal distribution of acute kidney injury–related hospitalizations after initiation of sodium–glucose cotransporter 2 inhibitors: A nationwide claims database analysis in older adults with an independent complementary single‐center eGFR analysis

Journal of Diabetes Investigation, EarlyView.
Among 190 older adults who experienced AKI‐related hospitalization after SGLT2 inhibitor initiation, 31.1% were hospitalized within 30 days. In an independent single‐center cohort, sustained early eGFR decline was associated with older age and use of one or two triple‐whammy‐related drug classes.
Kazuya Hiura, Ayana Tatsuno, Yamato Noto, Ryosuke Wakamatsu, Masayuki Sakunami, Ryu Kobayashi, Miki Yamashita   +6 more
wiley   +1 more source

Antihyperglycemic drug screening: 4-nitrophenol intermittent pulse amperometry as a convenient α-glucosidase inhibitor assay. [PDF]

RSC Adv
Prempinij W, Schulte A.
europepmc   +1 more source

Add-On Therapy with DPP-4 Inhibitors May Improve Renal Function Decline in α-Glucosidase Inhibitor and Metformin Users: A Retrospective Observational Study. [PDF]

Diabetes Metab Syndr Obes, 2020
Osonoi T, Saito M, Koda N, Douguchi S, Nakano T, Ofuchi K, Katoh M.   +6 more
europepmc   +1 more source

Effect of Sotagliflozin on Kidney Function and Cardio‐Kidney‐Metabolic Parameters Across Baseline eGFR Subgroups in Patients With Type 2 Diabetes and Stage 4 CKD

Diabetes, Obesity and Metabolism, EarlyView.
Vikas S. Sridhar, Luxcia Kugathasan, Manon Girard, Michael J. Davies, David Z. I. Cherney   +4 more
wiley   +1 more source

Frailty and low body mass index as key determinants of sodium‐glucose cotransporter 2 inhibitor‐specific adverse event‐related discontinuation in adults aged ≥75 years: A multicenter real‐world retrospective cohort study

Journal of Diabetes Investigation, EarlyView.
Among Japanese adults aged ≥75 years newly initiating SGLT2 inhibitors, SGLT2 inhibitor–specific adverse event‐related discontinuation occurred in 9.1% within 180 days. Frailty and low BMI, rather than chronological age, were the key predictors, highlighting the importance of assessing physiological reserve before treatment initiation.
Taisuke Uchida, Hiroaki Ueno, Ayaka Konagata, Hiroki Nabekura, Yuki Kikuchi, Takumi Beppu, Akari Sekishima, Hirotaka Sekishima, Takayuki Nakamura, Fumiko Kogo, Yudai Uehira, Yuri Tanaka, Hideki Yamaguchi, Kazuya Shimoda   +13 more
wiley   +1 more source

Vildagliptin Versus α-Glucosidase Inhibitor as Add-On to Metformin for Type 2 Diabetes: Subgroup Analysis of the China Prospective Diabetes Study. [PDF]

Diabetes Ther, 2020
Chen Y, Li Q, Han Y, Ji H, Gu M, Bian R, Ding W, Cheng J, Mu Y.   +8 more
europepmc   +1 more source